Japan· JP-7219420A2038
イオジキサノール
A iodixanol product containing イオジキサノール, registered in Japan by ＧＥヘルスケアファーマ, on the national reimbursement list. The same ATC class is registered in 16 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Iodixanol is registered in 16 of 19 countries.
Countries holding a registration under ATC V08AB09 (iodixanol), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 9 of them publish a price we can compare per daily dose
Iodixanol · ATC V08AB09
16 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- イオジキサノール
- Manufacturer
- ＧＥヘルスケアファーマ
- Country
- Japan (JP)
- ATC code
- V08AB09
- ATC class
- Iodixanol
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
172 interactions on record for iodixanol.
Graded by severity as the source publishes them — 87 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Iodixanol · interactions on record
172 records
- 87 severe
- 50 moderate
- 35 info
Most severe, free to view
- NeomycinA07AA01severe
- StreptomycinA07AA04severe
- Polymyxin BA07AA05severe
- Amphotericin BA07AA07severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under V08AB09
Iodixanol, as other registers publish it.
- United StatesIodixanolFRESENIUS KABI USA, LLC
- United StatesIodixanolFRESENIUS KABI USA, LLC
- FinlandVisipaqueGE Healthcare AS
- GermanyVisipaqueEurocontrast Gmbh
- GermanyVisipaqueGe Healthcare Buchler Gmbh & Co. Kg
- FinlandVisipaqueGE Healthcare AS
- NorwayVisipaqueGE Healthcare AS
- PolandVisipaqueGE Healthcare AS
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ce13c1d0-697a-48f8-b876-b9cea245c8eb GET /v1/drugs/ce13c1d0-697a-48f8-b876-b9cea245c8eb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５４．９７％５０ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "7219420A2038",
"category": "注射薬",
"price_yen": 3195,
"generic_name": "イオジキサノール",
"product_name_jp": null,
"therapeutic_class": "7219",
"transitional_expiry": null
}See everything about iodixanol.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.